Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Investigation of zinc‑copper alloys as potential materials for craniomaxillofacial osteosynthesis implants.

Li P, Zhang W, Dai J, Xepapadeas AB, Schweizer E, Alexander D, Scheideler L, Zhou C, Zhang H, Wan G, Geis-Gerstorfer J.

Mater Sci Eng C Mater Biol Appl. 2019 Oct;103:109826. doi: 10.1016/j.msec.2019.109826. Epub 2019 May 30.

PMID:
31349503
2.

Selection of extraction medium influences cytotoxicity of zinc and its alloys.

Li P, Schille C, Schweizer E, Kimmerle-Müller E, Rupp F, Heiss A, Legner C, Klotz UE, Geis-Gerstorfer J, Scheideler L.

Acta Biomater. 2019 Mar 9. pii: S1742-7061(19)30179-5. doi: 10.1016/j.actbio.2019.03.013. [Epub ahead of print]

PMID:
30862550
3.

Effect of slow-cooling protocol on biaxial flexural strengths of bilayered porcelain-ceria-stabilized zirconia/alumina nanocomposite (Ce-TZP/A) disks.

Sawada T, Wagner V, Schille C, Spintzyk S, Schweizer E, Geis-Gerstorfer J.

Dent Mater. 2019 Feb;35(2):270-282. doi: 10.1016/j.dental.2018.11.024. Epub 2018 Dec 3.

PMID:
30522698
4.

Comparative Analysis of Mechanical Properties and Metal-Ceramic Bond Strength of Co-Cr Dental Alloy Fabricated by Different Manufacturing Processes.

Han X, Sawada T, Schille C, Schweizer E, Scheideler L, Geis-Gerstorfer J, Rupp F, Spintzyk S.

Materials (Basel). 2018 Sep 22;11(10). pii: E1801. doi: 10.3390/ma11101801.

5.

Biaxial flexural strength of the bilayered disk composed of ceria-stabilized zirconia/alumina nanocomposite (Ce-TZP/A) and veneering porcelain.

Sawada T, Schille C, Wagner V, Spintzyk S, Schweizer E, Geis-Gerstorfer J.

Dent Mater. 2018 Aug;34(8):1199-1210. doi: 10.1016/j.dental.2018.05.003. Epub 2018 May 21.

PMID:
29793794
6.

Nine prophylactic polishing pastes: impact on discoloration, gloss, and surface properties of a CAD/CAM resin composite.

Liebermann A, Spintzyk S, Reymus M, Schweizer E, Stawarczyk B.

Clin Oral Investig. 2019 Jan;23(1):327-335. doi: 10.1007/s00784-018-2440-z. Epub 2018 Apr 16.

PMID:
29658069
7.

Mechanical Characteristics, In Vitro Degradation, Cytotoxicity, and Antibacterial Evaluation of Zn-4.0Ag Alloy as a Biodegradable Material.

Li P, Schille C, Schweizer E, Rupp F, Heiss A, Legner C, Klotz UE, Geis-Gerstorfer J, Scheideler L.

Int J Mol Sci. 2018 Mar 7;19(3). pii: E755. doi: 10.3390/ijms19030755.

8.

Influence of a surface conditioner to pre-sintered zirconia on the biaxial flexural strength and phase transformation.

Sawada T, Schille C, Zöldföldi J, Schweizer E, Geis-Gerstorfer J, Spintzyk S.

Dent Mater. 2018 Mar;34(3):486-493. doi: 10.1016/j.dental.2017.12.004. Epub 2018 Jan 1.

PMID:
29301652
9.

Influence of the Conditioning Method for Pre-Sintered Zirconia on the Shear Bond Strength of Bilayered Porcelain/Zirconia.

Spintzyk S, Yamaguchi K, Sawada T, Schille C, Schweizer E, Ozeki M, Geis-Gerstorfer J.

Materials (Basel). 2016 Sep 8;9(9). pii: E765. doi: 10.3390/ma9090765.

10.

Comparative evaluation of topographical data of dental implant surfaces applying optical interferometry and scanning electron microscopy.

Kournetas N, Spintzyk S, Schweizer E, Sawada T, Said F, Schmid P, Geis-Gerstorfer J, Eliades G, Rupp F.

Dent Mater. 2017 Aug;33(8):e317-e327. doi: 10.1016/j.dental.2017.04.020. Epub 2017 Jun 3.

PMID:
28587722
11.

Influence of Pre-Sintered Zirconia Surface Conditioning on Shear Bond Strength to Resin Cement.

Sawada T, Spintzyk S, Schille C, Zöldföldi J, Paterakis A, Schweizer E, Stephan I, Rupp F, Geis-Gerstorfer J.

Materials (Basel). 2016 Jun 25;9(7). pii: E518. doi: 10.3390/ma9070518.

12.

Influence of Different Framework Designs on the Fracture Properties of Ceria-Stabilized Tetragonal Zirconia/Alumina-Based All-Ceramic Crowns.

Sawada T, Spintzyk S, Schille C, Schweizer E, Scheideler L, Geis-Gerstorfer J.

Materials (Basel). 2016 May 5;9(5). pii: E339. doi: 10.3390/ma9050339.

13.

Influence of a bonding agent on the bond strength between a dental Co-Cr alloy and nine different veneering porcelains.

Al Bakkar H, Spintzyk S, Schille C, Schweizer E, Geis-Gerstorfer J, Rupp F.

Biomed Tech (Berl). 2016 Oct 1;61(5):509-517. doi: 10.1515/bmt-2015-0101.

PMID:
26966925
14.

Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature.

Baldwin DS, den Boer JA, Lyndon G, Emir B, Schweizer E, Haswell H.

J Psychopharmacol. 2015 Oct;29(10):1047-60. doi: 10.1177/0269881115598411. Epub 2015 Aug 10. Review.

PMID:
26259772
15.

Coating of ß-tricalcium phosphate scaffolds-a comparison between graphene oxide and poly-lactic-co-glycolic acid.

Ardjomandi N, Henrich A, Huth J, Klein C, Schweizer E, Scheideler L, Rupp F, Reinert S, Alexander D.

Biomed Mater. 2015 Aug 4;10(4):045018. doi: 10.1088/1748-6041/10/4/045018.

PMID:
26238604
16.

UV-A and UV-C light induced hydrophilization of dental implants.

Al Qahtani MS, Wu Y, Spintzyk S, Krieg P, Killinger A, Schweizer E, Stephan I, Scheideler L, Geis-Gerstorfer J, Rupp F.

Dent Mater. 2015 Aug;31(8):e157-67. doi: 10.1016/j.dental.2015.04.011. Epub 2015 May 15.

PMID:
25981907
17.

A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine.

Bhambri R, Mardekian J, Liu LZ, Schweizer E, Ramos E.

Int J Gen Med. 2015 Jan 12;8:27-36. doi: 10.2147/IJGM.S73673. eCollection 2015. Review.

18.

Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder.

Kasper S, Iglesias-García C, Schweizer E, Wilson J, DuBrava S, Prieto R, Pitman VW, Knapp L.

Int J Neuropsychopharmacol. 2014 May;17(5):685-95. doi: 10.1017/S1461145713001557. Epub 2013 Dec 19.

PMID:
24351233
19.

Cytocompatibility evaluation of different biodegradable magnesium alloys with human mesenchymal stem cells.

Niederlaender J, Walter M, Krajewski S, Schweizer E, Post M, Schille Ch, Geis-Gerstorfer J, Wendel HP.

J Mater Sci Mater Med. 2014 Mar;25(3):835-43. doi: 10.1007/s10856-013-5119-7. Epub 2013 Dec 11.

PMID:
24327112
20.

How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies.

Kasper S, Brasser M, Schweizer E, Lyndon G, Prieto R.

Eur Neuropsychopharmacol. 2014 Jan;24(1):125-32. doi: 10.1016/j.euroneuro.2013.10.015. Epub 2013 Nov 11.

PMID:
24290532
21.

Outcome for headache and pain-free nonresponders to treatment of the first attack: a pooled post-hoc analysis of four randomized trials of eletriptan 40 mg.

Landy SH, Tepper SJ, Schweizer E, Almas M, Ramos E.

Cephalalgia. 2014 Apr;34(5):376-81. doi: 10.1177/0333102413512035. Epub 2013 Nov 21.

PMID:
24265285
22.

Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study.

Almas M, Tepper SJ, Landy S, Schweizer E, Ramos E.

Cephalalgia. 2014 Feb;34(2):126-35. doi: 10.1177/0333102413500726. Epub 2013 Aug 14.

PMID:
23946318
23.

Influence of surface treatment on the wear of solid zirconia.

Kontos L, Schille C, Schweizer E, Geis-Gerstorfer J.

Acta Odontol Scand. 2013 May-Jul;71(3-4):482-7. doi: 10.3109/00016357.2012.696690. Epub 2012 Jul 2.

PMID:
23638857
24.

Identification of an aptamer binding to human osteogenic-induced progenitor cells.

Ardjomandi N, Niederlaender J, Aicher WK, Reinert S, Schweizer E, Wendel HP, Alexander D.

Nucleic Acid Ther. 2013 Feb;23(1):44-61. doi: 10.1089/nat.2012.0349. Epub 2013 Jan 4.

25.

An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.

Landy SH, Tepper SJ, Wein T, Schweizer E, Ramos E.

Headache. 2013 Jan;53(1):118-125. doi: 10.1111/j.1526-4610.2012.02295.x. Epub 2012 Nov 13.

PMID:
23148799
26.

Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?

Baldwin DS, Schweizer E, Xu Y, Lyndon G.

Eur Neuropsychopharmacol. 2012 Feb;22(2):137-42. doi: 10.1016/j.euroneuro.2011.07.005. Epub 2011 Aug 11.

PMID:
21839620
27.

Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study.

Greist JH, Liu-Dumaw M, Schweizer E, Feltner D.

Int Clin Psychopharmacol. 2011 Sep;26(5):243-51. doi: 10.1097/YIC.0b013e3283491fd5.

PMID:
21734588
28.

Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial.

Hadley SJ, Mandel FS, Schweizer E.

J Psychopharmacol. 2012 Apr;26(4):461-70. doi: 10.1177/0269881111405360. Epub 2011 Jun 21.

PMID:
21693549
29.

Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.

Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A.

Am J Psychiatry. 2011 Sep;168(9):957-67. doi: 10.1176/appi.ajp.2011.10060907. Epub 2011 Jun 15.

PMID:
21676992
30.

Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.

Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR.

Alcohol Clin Exp Res. 2011 Oct;35(10):1804-11. doi: 10.1111/j.1530-0277.2011.01524.x. Epub 2011 May 16.

PMID:
21575016
31.

Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.

Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R.

Int Clin Psychopharmacol. 2011 Jul;26(4):213-20. doi: 10.1097/YIC.0b013e32834519bd.

PMID:
21368587
32.

Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone.

O'Brien CP, Gastfriend DR, Forman RF, Schweizer E, Pettinati HM.

Am J Addict. 2011 Mar-Apr;20(2):106-12. doi: 10.1111/j.1521-0391.2010.00107.x. Epub 2010 Dec 28.

33.

PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease.

Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D.

Alzheimer Dis Assoc Disord. 2011 Jul-Sep;25(3):206-12. doi: 10.1097/WAD.0b013e318204b550.

34.

Interplay of structure, hydration and thermal stability in formacetal modified oligonucleotides: RNA may tolerate nonionic modifications better than DNA.

Kolarovic A, Schweizer E, Greene E, Gironda M, Pallan PS, Egli M, Rozners E.

J Am Chem Soc. 2009 Oct 21;131(41):14932-7. doi: 10.1021/ja904926e.

35.

Lurasidone: a new drug in development for schizophrenia.

Meyer JM, Loebel AD, Schweizer E.

Expert Opin Investig Drugs. 2009 Nov;18(11):1715-26. doi: 10.1517/13543780903286388. Review.

PMID:
19780705
36.

The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia.

Montgomery SA, Herman BK, Schweizer E, Mandel FS.

Int Clin Psychopharmacol. 2009 Jul;24(4):214-22. doi: 10.1097/YIC.0b013e32832dceb9.

PMID:
19542983
37.

Predicting and tuning physicochemical properties in lead optimization: amine basicities.

Morgenthaler M, Schweizer E, Hoffmann-Röder A, Benini F, Martin RE, Jaeschke G, Wagner B, Fischer H, Bendels S, Zimmerli D, Schneider J, Diederich F, Kansy M, Müller K.

ChemMedChem. 2007 Aug;2(8):1100-15. Review.

PMID:
17530727
38.

Mapping the fluorophilicity of a hydrophobic pocket: synthesis and biological evaluation of tricyclic thrombin inhibitors directing fluorinated alkyl groups into the p pocket.

Hoffmann-Röder A, Schweizer E, Egger J, Seiler P, Obst-Sander U, Wagner B, Kansy M, Banner DW, Diederich F.

ChemMedChem. 2006 Nov;1(11):1205-15.

PMID:
17001711
39.

A fluorine scan at the catalytic center of thrombin: C--F, C--OH, and C--OMe bioisosterism and fluorine effects on pKa and log D values.

Schweizer E, Hoffmann-Röder A, Schärer K, Olsen JA, Fäh C, Seiler P, Obst-Sander U, Wagner B, Kansy M, Diederich F.

ChemMedChem. 2006 Jun;1(6):611-21.

PMID:
16892401
40.

Multipolar interactions in the D pocket of thrombin: large differences between tricyclic imide and lactam inhibitors.

Schweizer E, Hoffmann-Röder A, Olsen JA, Seiler P, Obst-Sander U, Wagner B, Kansy M, Banner DW, Diederich F.

Org Biomol Chem. 2006 Jun 21;4(12):2364-75. Epub 2006 May 10.

PMID:
16763681
41.

Cloning, expression, and characterization of the human mitochondrial beta-ketoacyl synthase. Complementation of the yeast CEM1 knock-out strain.

Zhang L, Joshi AK, Hofmann J, Schweizer E, Smith S.

J Biol Chem. 2005 Apr 1;280(13):12422-9. Epub 2005 Jan 24.

42.

Microbial type I fatty acid synthases (FAS): major players in a network of cellular FAS systems.

Schweizer E, Hofmann J.

Microbiol Mol Biol Rev. 2004 Sep;68(3):501-17, table of contents. Review.

43.

Identification of the tRNA-binding protein Arc1p as a novel target of in vivo biotinylation in Saccharomyces cerevisiae.

Kim HS, Hoja U, Stolz J, Sauer G, Schweizer E.

J Biol Chem. 2004 Oct 8;279(41):42445-52. Epub 2004 Jul 22.

44.

HFA1 encoding an organelle-specific acetyl-CoA carboxylase controls mitochondrial fatty acid synthesis in Saccharomyces cerevisiae.

Hoja U, Marthol S, Hofmann J, Stegner S, Schulz R, Meier S, Greiner E, Schweizer E.

J Biol Chem. 2004 May 21;279(21):21779-86. Epub 2004 Feb 3.

45.

Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy.

Rynn M, García-España F, Greenblatt DJ, Mandos LA, Schweizer E, Rickels K.

J Clin Psychopharmacol. 2003 Oct;23(5):505-8.

PMID:
14520129
46.

Functional differentiation and selective inactivation of multiple Saccharomyces cerevisiae genes involved in very-long-chain fatty acid synthesis.

Rössler H, Rieck C, Delong T, Hoja U, Schweizer E.

Mol Genet Genomics. 2003 May;269(2):290-8. Epub 2003 Mar 26.

PMID:
12684876
47.
48.

Abnormal salivary cortisol levels in social phobic patients in response to acute psychological but not physical stress.

Furlan PM, DeMartinis N, Schweizer E, Rickels K, Lucki I.

Biol Psychiatry. 2001 Aug 15;50(4):254-9.

PMID:
11522259
49.

The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial.

Schweizer E, Rynn M, Mandos LA, Demartinis N, García-España F, Rickels K.

Int Clin Psychopharmacol. 2001 May;16(3):137-43.

PMID:
11354235
50.

A novel function of yeast fatty acid synthase. Subunit alpha is capable of self-pantetheinylation.

Fichtlscherer F, Wellein C, Mittag M, Schweizer E.

Eur J Biochem. 2000 May;267(9):2666-71.

Supplemental Content

Loading ...
Support Center